News

The U.S. Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients.…
Read More...

GSK has reported positive Phase II results for its mRNA seasonal influenza vaccine candidate, with the company planning to begin a Phase III efficacy trial in September 2026. The…
Read More...

Médunik Canada has entered into an exclusive promotional services agreement with Biocodex for Diacomit®, a treatment used for seizures associated with Dravet syndrome in Canada.…
Read More...

Superluminal Medicines has raised $60 million in an oversubscribed Series B financing to advance its drug development programs, including a lead treatment for rare genetic forms of…
Read More...

Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in adults with relapsing multiple sclerosis (RMS). The oral…
Read More...

Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical to support the research and development of a fully human VHH antibody for…
Read More...

Typewriter Therapeutics has emerged from stealth with $56 million in Series A financing to develop genetic medicines for cancer, autoimmune diseases, and severe genetic disorders.…
Read More...

Cipla Limited and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing and supply agreement for TQB2102, an…
Read More...

The U.S. Food and Drug Administration (FDA) has approved PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making…
Read More...

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced a shared commitment with the Trump Administration to explore ways to lower the cost of…
Read More...

Kazia Therapeutics Limited has closed an oversubscribed public offering that generated approximately $40 million in upfront gross proceeds, providing additional funding for the clinical…
Read More...

SK Biopharmaceuticals has agreed to in-license opakalim, an investigational anti-seizure medicine from Biohaven, in a deal that could reach $795 million and could help the South Korean…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted Kowa Pharmaceuticals America’s New Drug Application (NDA) for K-911, an investigational eye drop being developed to reduce…
Read More...

AusperBio Therapeutics has raised $120 million in a Series C financing round to support the development of its experimental treatments for chronic hepatitis B (CHB) and prepare its lead…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Priovant Therapeutics’ LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM), a rare autoimmune…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at…
Read More...

BioXcel Therapeutics has entered into an agreement with Teva Pharmaceuticals International GmbH for the sale of substantially all of its assets as the biotechnology company begins…
Read More...

The U.S. Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in children weighing at least 2 kg. The…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to ReviR Therapeutics’ investigational drug RTX-117 for the treatment of…
Read More...

The U.S. Food and Drug Administration (FDA) has approved two Ziihera (zanidatamab-hrii)-based treatment regimens for the first-line treatment of adults with unresectable locally…
Read More...